Answers are grounded in this paper and cite their sources.
Our placebo-controlled randomized trial suggests that liraglutide has renoprotective effects on top of multifactorial treatment, including RAS-inhibition, in patients with type 2 diabetes and albuminuria.
No takes yet. Share an insight, caveat, or question.
Scholten et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: